A detailed history of Tkg Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Tkg Advisors, LLC holds 759 shares of VRTX stock, worth $360,198. This represents 0.18% of its overall portfolio holdings.

Number of Shares
759
Previous 773 1.81%
Holding current value
$360,198
Previous $314,000 0.96%
% of portfolio
0.18%
Previous 0.19%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 01, 2024

SELL
$407.69 - $446.08 $5,707 - $6,245
-14 Reduced 1.81%
759 $317,000
Q4 2023

Feb 23, 2024

SELL
$343.0 - $410.68 $45,962 - $55,031
-134 Reduced 14.77%
773 $314,000
Q3 2023

Nov 02, 2023

BUY
$338.18 - $362.46 $1,690 - $1,812
5 Added 0.55%
907 $315,000
Q2 2023

Jul 20, 2023

SELL
$314.42 - $351.91 $141,803 - $158,711
-451 Reduced 33.33%
902 $317,000
Q1 2023

Apr 19, 2023

BUY
$283.23 - $323.1 $283 - $323
1 Added 0.07%
1,353 $426,000
Q4 2022

Jan 27, 2023

BUY
$285.76 - $321.48 $386,347 - $434,640
1,352 New
1,352 $390,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Tkg Advisors, LLC Portfolio

Follow Tkg Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tkg Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tkg Advisors, LLC with notifications on news.